Physician profile
Marwan Badri
NPI 1265744908
$2,946.51
in general payments reported to CMS, 2019-2025
18 companies · $679 in 2025
The $679 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $28.90 · 2021: $366 · 2022: $118 · 2023: $491 · 2024: $542 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,217.82 | 2019-2025 | Avvigo Guidance System, Rotapro, Opticross |
| Medtronic, INC. | $427.31 | 2021-2025 | Symplicity G3 |
| Medtronic Vascular, INC. | $358.43 | 2019-2020 | |
| Shockwave Medical, INC | $181.97 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Angiodynamics, INC. | $127.80 | 2025 | Alphavac |
| Heartflow, INC. | $114.84 | 2023 | Ffrct |
| Penumbra, INC. | $113.42 | 2019 | |
| Abbott Laboratories | $90.61 | 2019 | |
| Abiomed | $74.50 | 2021-2022 | |
| Amgen INC. | $67.91 | 2022-2025 | Repatha |
| Acist Medical Systems, INC. | $43.28 | 2023 | |
| Janssen Pharmaceuticals, INC | $39.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.61 | 2019 | |
| Cardiovascular Systems INC. | $15.12 | 2019 | |
| Pfizer INC. | $14.58 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $14.25 | 2025 | Qdot Micro |
| Biotronik INC. | $13.19 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwan Badri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.